AstraZeneca: Camizestrant Significantly Delayed Disease Progression In Advanced ER-Positive Breast Cancer, Adding At Least 3.5 Months Benefit Versus FASLODEX (Fulvestrant)
December 09, 2022
December 09, 2022
WILMINGTON, Delaware, Dec. 9 -- AstraZeneca, a biopharmaceutical company, issued the following news release on Dec. 8, 2022:
Detailed results from the SERENA-2 Phase II trial showed AstraZeneca's next-generation oral selective estrogen receptor degrader (ngSERD) camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) at both 75mg and 150mg dose levels versus FASLODEX(R) (fulvestrant) 500mg in post-menopausal . . .
Detailed results from the SERENA-2 Phase II trial showed AstraZeneca's next-generation oral selective estrogen receptor degrader (ngSERD) camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) at both 75mg and 150mg dose levels versus FASLODEX(R) (fulvestrant) 500mg in post-menopausal . . .